Key result
Sustained inhibition of endopeptidase 24.11 significantly enhanced plasma atrial natriuretic peptide (P<0.05) but suppressed plasma brain natriuretic peptide (P<0.01) in essential hypertension.
Why the study?
Does inhibition of endopeptidase 24.11, change in posture, or angiotensin II infusion alter plasma brain natriuretic peptide levels in patients with essential hypertension?
RCT
Double-blind
random-order crossover
Does inhibition of endopeptidase 24.11, change in posture, or angiotensin II infusion alter plasma brain natriuretic peptide levels in patients with essential hypertension?
p-value: p=<.01
In patients with essential hypertension, endopeptidase 24.11 inhibition suppresses brain natriuretic peptide despite enhancing atrial natriuretic peptide, suggesting BNP is primarily regulated by left ventricular load rather than atrial distending pressure.
No takes yet. Share an insight, caveat, or question.
Endopeptidase 24.11 inhibition differentially modulates natriuretic peptides in hypertension; extends evidence that BNP is regulated by ventricular load rather than atrial pressure.
Richards et al. (1993) conducted an RCT in essential hypertension. Endopeptidase 24.11 inhibitors (SCH 42495 or UK 79300) vs. Placebo was evaluated on Plasma atrial natriuretic peptide and plasma brain natriuretic peptide levels (p=<.01). Sustained inhibition of endopeptidase 24.11 significantly enhanced plasma atrial natriuretic peptide (P<0.05) but suppressed plasma brain natriuretic peptide (P<0.01) in essential hypertension.